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eligible. Direct sequencing using DNA extracted from parafﬁn-embed-
ded tumor specimens to detect mutations in EGFR (exons 18, 19 and 
21) was performed in a central laboratory, and the median time for 
the analysis required 12 days (range 7-28). The primary objective was 
the objective response rate of geﬁtinib in NSCLC patients with EGFR 
mutations. With the target activity level of 50% and the lowest response 
rate of interest set at 25%, 23 eligible patients were required to accept 
the hypothesis. 
Results: Between March 2005 and January 2006, EGFR mutations 
were detected in 32 patients (27%) in 118 screened NSCLC patients. 
EGFR mutations were signiﬁcantly frequent in females, in adenocar-
cinoma histology and never smoker. Twenty-eight of the 32 patients 
have been enrolled onto this study; 14 patients had deletional mutations 
in exon 19 and 14 patients had missense mutations in exon 21. Of the 
28 patients with EGFR mutations: adenocarcinoma (27), female (18) 
and never smoker (19). Overall response rate was 77.8 % and disease 
control rate was 100% ( 1 CR, 20 PR, 6 SD, 1 NE and no PD ). The 
median PFS time was 10.8 months (95% Cl. 7.3 months to -). The 
median OS has not yet been reached, and 1Y-S was 80%. In the subset 
analysis of PFS, there was no signiﬁcant difference between sex (male 
vs. female), PS (PS0/1 vs. PS2), number of prior regimens (0 vs. 1/2) 
and the site of EGFR mutations (exon 19 vs. exon 21). 1Y-S of exon 19 
was 92.9% and exon 21 was 68.8%. There was no signiﬁcant differ-
ence. The most common toxicities (grade 2-4) were rash observed in 
13 (46%) patients, dry skin in 10(36%) patients and elevated AST/ALT 
in 6(21%) patients. Interstitial lung disease was occurred in 3(11%) pa-
tients (2pts:Grade1, 1pt:Grade4). There was no treatment related death. 
Conclusions: These data prospectively veriﬁed the validity of EGFR 
mutations as an important predictor of geﬁtinib responsiveness. A mul-
ticenter phase II with patient’s selection by central EGFR gene review 
has successfully done.
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Introduction: CT is the standard of care for patients with metastatic 
NSCLC. The use of EGFR inhibitors has an emerging role in this dis-
ease but it is not clear the potential beneﬁt of adding these drugs in the 
ﬁrst line setting. This meta-analysis aims to quantify the treatment ef-
fect of EGFR inhibitors plus standard CT in the treatment of advanced 
NSCLC and compare the combination to standard CT.
Purpose: analyze the efﬁcacy and safety of the addition of EGFR-
TKIs, Geﬁtinib or Erlotinib and Cetuximab to the standard chemothera-
py in chemo-naïve patients with advanced NSCLC.
Patients and methods: We have made an extensive search in the 
PubMed, looking for randomized trials (RT) in untreated patients with 
locally advanced or metastatic NSCLC, that compare standard platinum 
based chemotherapy with or without anti -EGFR agents. We found ﬁve 
RT that matched with our search criteria: four RT compare EGFR-TKIs 
with chemotherapy versus standard chemotherapy, and one Phase II 
RT that explored the addition of Cetuximab in the ﬁrst line setting. We 
used the Mantel-Haenszel method to calculate the weighted summary 
Odds ratio (OR) under the ﬁxed and random effects model.
Results: Data from a total of 3632 patients from 5 randomized trials 
were included. 
 
EGFR 
inhibitor+CT
Chemotherapy OR (95% CI) P value
ORR 584/1814 pts 546/1820 pts 1.11 (0.92-1.23) NS
1-year OS 764/1771 pts 754/1777 pts 1.03 (0.90-1.18) NS
Overall Surv. 1292/1812 pts 1293/1820 pts 1.01 (0.87-1.17) NS
Rash Gr 3/4 354/1406 pts 283/1416 pts 1.44 (1.19-1.75) <0.001
Diarrhea Gr 3/4 110/1236 pts 24/1241 pts 3.93 (2.09-5.22 <0.001
 
No differences were found in all the efﬁcacy endpoints evaluated, 
including overall survival, 1 year survival, overall response. Regard-
ing toxicity there was a signiﬁcant increase in rash and diarrhea. No 
signiﬁcant difference were observed neither in the incidence of lung 
interstitial disease nor in other safety parameters.
Conclusions: The combination of standard chemotherapy with EGFR 
inhibitors did not neither improve survival, progression free survival, 
nor response rate compared with chemotherapy given alone. These 
results conﬁrm the lack of beneﬁt of this strategy in unselected patient 
population. Further investigations are required to identify potential sub-
group of patients who could beneﬁt with the addition of these agents 
including sequential strategies.
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Background: The optimal strategy in advanced NSCLC with stable 
disease is not well known. The sequence and the drugs are not deﬁned.
Purpose: To evaluate the efﬁcacy and safety of early modiﬁcation of 
chemotherapy doublets in patients with advanced non small cell lung 
cancer with stable disease (SD).
Methods: Patients with stage IV NSCLC and measurable disease were 
included in a randomized phase II trial comparing for patients with 
stable disease after 2 cycles of a platin (P)-gemcitabine doublet (P d1: 
75 mg/m2, gemcitabine 1 250 mg/m2 d1, d8 every three weeks) two 
subsequent cycles of this doublet (arm A) to a switch to another doublet 
(arm B): paclitaxel 100 mg/m2 d1, d8, d15, gemcitabine 1 250 mg/m2 
d1, d8, every four weeks. 
Results: Between October 2003 and august 2006, 228 patients (pts) 
were enrolled (187 males, 41 females), median age 57 y (30-70). 
Evaluation (EVA) 1 showed 98 patients (43%) with stable diseases (87 
patients were randomized). 48.3% were PS0, 51.7% PS1; 41.4% had 
only one metastatic site. Efﬁcacy at eva 2 is depicted above. Overall 
survival (OS) was similar between the two arms: 9.8 months (m) [7.0 
Copyright © 2007 by the International Association for the Study of Lung Cancer S745
Journal of Thoracic Oncology • Volume 2, Number 8, Supplement 4, August 2007  12th World Conference on Lung Cancer
- 14.2] for arm A, 9.2 m [7.4 - 10.5] for arm B. TTP was 5.4 m in arm 
A and 5.7 in arm B. There were 1 grade III/IV haematological toxicities 
in arm A (1.2%) and 2 in arm B (2.4%). There were 4 grade III/IV non 
haematological toxicities in arm A (4.8%) and 6 in arm B (7.3%). 
Conclusion: The switch between the two regimen is feasible without 
any major toxicities. Despite higher response rate in favour of the 
switch strategy, OS and TTP are similar between the two arms. A new 
censor date is ﬁxed at 1st June 2007. Overall survival and TTP will be 
updated for a ﬁnal analysis.
SD n = 87 PD (%) SD (%) OR (%) NA (%)
Arm A (n = 45) 24.4 53.3 15.6 6.6
Arm B (n = 42) 11.9 59.5 21.4 7.1
95% CI ORR ; Arm A: 15.6 [6.49 - 29.45] ;  Arm B: 21.4 [10.3 - 36.81]
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Background: Imatinib inhibits activated PDGF-Rβ and down-regu-
lates VEGF resulting in decreased angiogenesis and improved blood 
ﬂow favoring enhanced tumor drug delivery. 
Objectives: 1) determine the MTD for the combination of imatinib and 
cisplatin plus docetaxel in NSCLC pts, 2) describe non-dose limiting 
toxicities (non-DLT), 3) evaluate for feasibility and changes tumor 
angiogenesis measurement by DCE-MRI after treatment with imatinib. 
DCE-MRI detects speciﬁc properties of vascular beds by virtue of the 
differential distribution of contrast media in normal and pathological 
regions. 
Methods: Eligibility: NSCLC with tumor expression of p-PDGF-Rβ. 
DCE-MRI was performed before and after 7 daily doses of imatinib 
alone (lead-in) followed by cisplatin plus docetexel on day 1, every 
3 weeks. Once daily imatinib was given with each cisplatin plus 
docetaxel cycle, on days -5 to +2. Standardized hemodynamic param-
eters (Ktrans, Ve, Kep) were acquired from DCE-MRI. 
Results: 14 enrolled pts (9 M, 5 F) were evaluable for toxicity and 13 
for response. Six pts were treated at dose level 1 (C+D 60/60 mg/m2, 
and I 300 mg); one DLT (febrile neutropenia) was seen; there were 
no DLTs in cohort 2 (60/60 mg/m2 and I 400mg; n=3), and two DLTs 
were observed in cohort 3 (70/70 mg/m≥ and I 400mg; n=5) - febrile 
neutropenia and grade 4 diarrhea. For all cohorts, grade 3 and 4 toxici-
ties were: fatigue (7%), nausea (14%), neutropenia (14%), elevated 
creatinine (7%), and dispnea (7%). Two pts (15%) had partial response, 
and 6/13 pts had stable disease as their best response. DCE-MRI dem-
onstrated trend in decrease of Ve after 7-day treatment with imatinib 
(p=0.088). 
Conclusion: MTD for imatinib and cisplatin plus docetaxel in chemo 
naïve NSCLC pts is 400 mg and 60/60 mg/m≥, respectively. More, 
DCE-MRI is feasible in NSCLC pts. DCE-MRI measured reduction 
in tumor extracellular extravascular space (Ve) suggests decrease in 
intra-tumoral pressure after PDGF-Rβ inhibition, which could mean 
improvement in tumor drug delivery. Further studies exploring DCE-
MRI as an imaging biomarker-predictor to antiangiogenic therapy in 
patients with NSCLC are ongoing.
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Background: Brain metastases are a common feature of non-small-
cell lung cancer (NSCLC) and are gaining more and more attention, 
as combined modality treatment and efﬁcient new drug therapies have 
improved local control and overall survival rates. The clinical man-
agement of brain metastases is of critical importance to prevent rapid 
disease deterioration and symptom-driven worsening of quality of 
life. Therapeutic options for cranial progression after previous whole 
brain irradiation and chemotherapy-induced tumor remission are very 
limited. No established therapeutic approaches exist for cranial relapse 
after response to previous radiotherapy and systemic chemotherapy. 
Casuistry reporting of experiences with new agents in such patients 
may help to build up a rationale for new therapy sequences in this hard-
to-treat patient population.
Methods: Presented are two case reports arising from our hospitals’ 
two-years lasting clinical experience with erlotinib, a TK-EGFR-in-
hibitor approved to treat patients with locally advanced or metastatic 
NSCLC after failure of at least one prior chemotherapy regimen. Erlo-
tinib was used in accordance with prescribing information as third-line 
therapy in two non-smoking women, one with adenocarcinoma and the 
other one with bronchioloalveolar carcinoma histology. Both patients 
were initially staged M+ due to distant lymph node and contra-lateral 
pulmonary tumor manifestation.
Results: After occurrence of brain metastases in autumn 2004, both 
patients underwent standard whole brain irradiation with 40 Gy. The 
well-tolerated radiotherapy was followed by second-line chemotherapy 
which resulted in both cases into a consolidation of the thoracic and 
cranial tumor manifestation for around six months. Pulmonary and 
cerebral progression requested in both cases for a therapeutic alter-
native. Tyrosine kinase (TK) inhibition began in July respectively 
October 2005. In the ﬁrst patient, therapy was stopped despite ongoing 
cranial and pulmonary remission after 9 months due to the appear-
ance of hepatic metastasis. In the second patient, erlotinib therapy was 
continued for 15 months with a lasting cranial (CR) and thoracic (PR) 
remission. Surgery (partial laminectomy of axis and atlas) plus post-op-
erative cranial-cervical irradiation (40 Gy) were adequate measures to 
control beginning osseous metastasis in September 2006. After signs of 
pulmonary recurrence, therapy was stopped in December 2006. In both 
patients, the therapy was well tolerated with minimal side effects and 
improved quality of life scores. With view to the generally poor prog-
nosis of metastatic brain cancer with its median survival of 3-4 months, 
the sustained objective remission and control of cranial metastases for 
about 9 respectively more than 15 months is noteworthy.
Conclusions: The ability of TK-inhibitors as erlotinib to induce objec-
tive remissions in brain metastases which occurred after initial whole 
brain irradiation and which relapsed after previous chemotherapy, 
requires attention. The observed total survival times of above 18 
